Table 4.
Tumor Responses
| Overall (N=27) | Cohort I (N=15) | Cohort II (N=12) | |
|---|---|---|---|
|
| |||
| Best Response | |||
| Partial Response | 2 (7.4%) | 0 | 2 (16.7%) |
| Stable Disease | 10 (37%) | 9 (60%) | 1 (8.3%) |
| Progressive Disease | 11 (40.7%) | 6 (40%) | 5 (41.7%) |
| Too Early to Assess* | 4 (14.8%) | 0 | 4 (33.3%) |
One patient discontinued due to adverse events, three refused further participation